BINDING MOLECULE SPECIFIC TO LRIG-1 PROTEIN, AND USE THEREOF
The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French German |
Published |
27.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune diseases, graft-versus-host diseases, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory diseases. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto. |
---|---|
Bibliography: | Application Number: EP20190872549 |